Praxis Pesquisa Medica

Santo André, São Paulo 09790790

2 studies enrolling now · 8 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, COVID-19, Crohn's Disease, Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Obesity, Overweight, Pneumonia, Sickle Cell Disease, Ulcerative Colitis

Studies at this site

• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — Recruiting now
• A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) — Running, not enrolling
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Running, not enrolling
• ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• A Study of Baricitinib (LY3009104) in Participants With COVID-19 — Completed
• Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) — Completed